JMP Securities downgraded Allakos (ALLK) to Market Perform from Outperform without a price target after the company’s Phase 1 clinical trial of AK006 in chronic spontaneous urticaria did not yield to clinical benefit. Allakos decided to discontinue further clinical development of AK006.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLK:
- Piper downgrades Allakos to Neutral with only asset discontinued
- Allakos downgraded to Neutral from Overweight at Piper Sandler
- Allakos to discontinue further clinical development of AK006, cut workforce 75%
- Allakos Restructures Amid AK006 Program Discontinuation
- Allakos Restructures Amid AK006 Discontinuation and Layoffs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue